Skip to Main Content


Skip Nav Destination


In This Issue

In the Spotlight


Research Articles

Atezolizumab shows promising activity with durable responses in immunotherapy-naive patients with a tumor mutation burden (TMB) of ≥16 mut/Mb across a variety of advanced solid tumors, but limited activity was observed in patients with a TMB between 10 and 16 mut/Mb.

Single-cell RNA sequencing analysis of over 200,000 gastric cancer cells forms a comprehensive molecular atlas, identifying novel cell lineages and unique interactions between tumor cells and the surrounding microenvironment.

Neuroendocrine carcinomas (NEC) of the gastrointestinal system show similar histopathologic features and share some genomic features, but considerable differences exist between pancreatic NECs and nonpancreatic NECs.

Targeted degradation of EP300 with a novel PROTAC agent in neuroblastoma cells was found to cause widespread loss of gene expression and cell death in vitro and in vivo.

PTP1B functions as an intracellular checkpoint that limits the cytotoxic activity of tumor-infiltrating T cells, and its deletion or inhibition can enhance the antitumor immunity of T cells and CAR T cells and the response to anti–PD-1 therapy.

Depletion of mitochondrial iron with the drug ironomycin induced a dramatic loss in mitochondrial respiration and noncanonical BAX/BAK-dependent cell death that synergized with venetoclax in mouse and patient-derived models of leukemia.

News in Brief

News in Depth

Research Watch

Clinical Trials
Disease Prevalence
Drug Evaluation
Drug Resistance
Drug Combinations
Breast Cancer
Disease Progression


Close Modal

or Create an Account

Close Modal
Close Modal